Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » NovoSeven RT 250KIU


To avoid
As a precautionary measure

Contraindicated
NovoSeven RT 250KIU :
Type Medicine Authorised
Originator Biotech (NovoSeven RT 250KIU)
Agent Mersaco
Distributor Mersaco
Laboratory Novo Nordisk
Responsible Party Novo Nordisk AS
Origin Denmark
Manufacturer Novo Nordisk AS
Origin Denmark
ATC B02BD08

Your comment will appear shortly after approval

NovoSeven RT 250KIU :

Revision Date : 18/12/2013


Effect Frequency
ALT increased Rare
Anaphylactic reactions Not known
Angina pectoris Rare
Angioedema (Angioneurotic oedema) (Quincke oedema) Not known
Antithrombin III decreased Rare
Blood alkaline phosphatase increased Rare
Blood lactate dehydrogenase increased Rare
Cardiac arrest Not known
Cerebral artery occlusion Rare
Cerebral infarction Rare
Cerebral ischaemia Rare
Cerebrovascular accident Rare
Coagulopathy Rare
Deep vein thrombosis Uncommon
Dermatitis allergic Uncommon
Disseminated intravascular coagulation Rare
Drug ineffective Not known
Fibrin D dimer increased Rare
Fibrin degradation products increased Rare
Flushing Not known
Headache Rare
Hypersensitivity Rare
Inhibiting antibodies Not known
Injection site pain Rare
Injection site reaction Rare
Intestinal ischaemia Rare
Intracardiac thrombus Not known
Myocardial infarction Rare
Nausea Rare
Peripheral artery thrombosis Rare
Peripheral ischaemia Rare
Portal vein thrombosis Uncommon
Prothrombin level increased Rare
Pruritus Uncommon
Pulmonary embolism Uncommon
Pyrexia Uncommon
Rash erythematous Uncommon
Renal artery thrombosis Rare
Renal vein thrombosis Uncommon
Skin rash Uncommon
Therapeutic response decreased Uncommon
Thromboembolic event Uncommon
Thromboembolism arterial Rare
Thromboembolism venous Uncommon
Thrombophlebitis Uncommon
Thrombophlebitis superficial Uncommon
Urticaria Uncommon
Vessel puncture site thrombosis Uncommon

Different Units By MoH Code

Revision Date : 11/01/2013

NovoSeven RT 250KIU  MoH 5541 :
Form Powder and solvent for solution for injection
Packaging Pre-filled Syringes + Vials (Type I glass)
Package Size 1+1
Strength 5mg (250KIU)
Public Price 4222855 L.L.
Stratum E2
NSSF ✔
Quarantine ✘
Reg. Number 218017/09
Submission date 01/01/2009
Registration Year 2009


Price Comparison

● Country: Italy
● Package Size: 1+1x5.2ml
● Public Price: 5395.61 EUR ( 522,705,114.36 LBP )
● Pack size unit used: 1
● Cost/Unit: 5395,61 EUR ( 522,646,020.00 LBP )
● Exfactory Price: 3269.25 EUR
● Pricing Date: 17/12/2019
● Type: Medicine Authorised

● Country: Qatar
● Package Size: 1 powder vial + 1 Solvent pre-filled syringe + vial adapter
● Public Price: 19816 QAR ( 486,641,328.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 19816 QAR ( 486,641,328.00 LBP )
● Pharmacy Price: 16277.33865628 QAR ( 399738882.72092 LBP )
● Pricing Date: 28/01/2021
● Type: Medicine Authorised

● Country: Oman
● Package Size: 1+1
● Public Price: 2086.42 OMR ( 481,408,032.28 LBP )
● Pack size unit used: 1
● Cost/Unit: 2086,42 OMR ( 481,311,124.00 LBP )
● Pricing Date: 19/02/2021
● Type: Medicine Authorised

● Country: Kuweit
● Package Size: 1+1
● Public Price: 1596.98 KWD ( 468,842,985.38 LBP )
● Pack size unit used: 1
● Cost/Unit: 1596,98 KWD ( 468,555,276.00 LBP )
● Pharmacy Price: 1349.17 KWD ( 396090677.77 LBP )
● Pricing Date: 07/02/2021
● Type: Medicine Authorised

● Country: Switzerland
● Package Size: 1+1
● Public Price: 4370.8 CHF ( 452,028,136.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 4370,8 CHF ( 451,945,400.00 LBP )
● Exfactory Price: 4224.2 CHF
● Pricing Date: 04/04/2021
● Type: Medicine Authorised

● Country: Abu Dhabi
● Package Size: 1+1
● Public Price: 18517 AED ( 447,389,237.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Pharmacy Price: 15773.8 AED ( 381110781.8 LBP )
● Pricing Date: 27/01/2021
● Type: Medicine Authorised

● Country: UAE
● Package Size: 1 Vial (Powder) + 1 Solvent Vial (2.1ml)
● Public Price: 18517 AED ( 447,389,237.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Pharmacy Price: 15773.78 AED ( 381110298.58 LBP )
● Pricing Date: 21/08/2019
● Type: Medicine Authorised

● Country: Bahrain
● Package Size: 1+1
● Public Price: 1761.26 BHD ( 418,711,384.84 LBP )
● Pack size unit used: 1
● Cost/Unit: 1761,26 BHD ( 418,649,574.00 LBP )
● Reference: nhra
● Pricing Date: 09/02/2021
● Type: Medicine Authorised

● Country: Finland
● Package Size: 1+1
● Public Price: 3888.15 EUR ( 376,668,419.40 LBP )
● Pack size unit used: 1
● Cost/Unit: 3888,15 EUR ( 376,653,888.00 LBP )
● Reference: Kela
● Pricing Date: 22/04/2021
● Type: Medicine Authorised

● Country: Denmark
● Package Size: 1+1
● Public Price: 26563.3 DKK ( 344,685,380.80 LBP )
● Pack size unit used: 1
● Cost/Unit: 26563,3 DKK ( 344,681,488.00 LBP )
● Pharmacy Price: 19744.6 DKK ( 256205929.6 LBP )
● Reference: Danish Medicine Agency
● Pricing Date: 19/05/2021
● Type: Medicine Authorised

● Country: Iceland
● Package Size: 1+1
● Public Price: 532896 ISK ( 343,717,920.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 532896 ISK ( 343,717,920.00 LBP )
● Pharmacy Price: 423362 ISK ( 273068490 LBP )
● Reference: Icelandic Medicines Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Czech Republic
● Package Size: 1+1x5.2ml
● Public Price: 85264.46 CZK ( 325,624,972.74 LBP )
● Pack size unit used: 1
● Cost/Unit: 85264,46 CZK ( 325,623,216.00 LBP )
● Reference: SUKL
● Pricing Date: 28/02/2020
● Type: Medicine Authorised

● Country: KSA
● Package Size: 3mg
● Public Price: 13202.15 SAR ( 312,098,826.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 13202,15 SAR ( 312,095,280.00 LBP )
● Reference: sfda
● Pricing Date: 16/01/2021
● Type: Medicine Authorised

● Country: UK
● Package Size: 1+1
● Public Price: 2626 GBP ( 298,442,274.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 2626 GBP ( 298,442,274.00 LBP )
● Reference: DMD
● Pricing Date: 08/03/2021
● Type: Medicine Authorised

● Country: Spain
● Package Size: 1 vial + 1xdisolvente
● Public Price: 3062.98 EUR ( 296,729,250.48 LBP )
● Pack size unit used: 1
● Cost/Unit: 3062,98 EUR ( 296,634,312.00 LBP )
● Reference: Agencia Española de Medicamentos y Productos Sanitarios
● Pricing Date: 06/05/2021
● Type: Medicine Non Marketed

● Country: France
● Package Size: 1+1
● Public Price: 3040 EUR ( 294,503,040.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 3040 EUR ( 294,503,040.00 LBP )
● Reference: ansm
● Pricing Date: 15/05/2021
● Type: Medicine Authorised

● Country: Belgium
● Package Size: 1+1x5.2ml
● Public Price: 2662 EUR ( 257,883,912.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 2662 EUR ( 257,883,912.00 LBP )
● Medica Comments: Withdrawn on november 2018
● Reference: cbip
● Pricing Date: 02/12/2020
● Type: Medicine Authorised

● Country: Norway
● Package Size: 1
● Public Price: 30097 NOK ( 243,906,088.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 30097 NOK ( 243,906,088.00 LBP )
● Pharmacy Price: 23577.07 NOK ( 191068575.28 LBP )
● Reference: Norwegian Medicine Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Sweden
● Package Size: 1+1
● Public Price: 28482.76 SEK ( 239,483,046.08 LBP )
● Pack size unit used: 1
● Cost/Unit: 28482,76 SEK ( 239,476,656.00 LBP )
● Pharmacy Price: 27878.93 SEK ( 234406043.44 LBP )
● Pricing Date: 23/04/2020
● Type: Medicine Authorised

● Country: Turkey
● Package Size: 1
● Public Price: 12895.82 TRY ( 34,560,797.60 LBP )
● Pack size unit used: 1
● Cost/Unit: 12895,82 TRY ( 34,558,600.00 LBP )
● Pricing Date: 28/10/2020
● Type: Medicine Authorised

● Country: Lebanon
● Form: Powder and solvent for solution for injection
● Package Size: 1+1
● Public Price: 4222855 LBP ( 4,222,855.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 4222855 LBP ( 4,222,855.00 LBP )
● Pricing Date: 13/06/2024

● Country: The Netherlands
● Package Size: 1
● Reference: Zorginstituut Nederland
● Pricing Date: 15/06/2019
● Type: Medicine Non Marketed

● Country: Greece
● Package Size: 1+1
● Reference: National Organization for Medicines
● Pricing Date: 25/03/2019
● Type: Medicine Non Marketed

● Country: New Zealand
● Package Size: 1 inj
● Exfactory Price: 5891.5 NZD
● Reference: New Zealand Pharmaceutical Management Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Portugal
● Package Size: 1+1
● Reference: Autoridade Nacional do Medicamento e Produtos de Saúde
● Pricing Date: 22/04/2019

    ◼ Lebanon
    ◼ Country of Origin
    ◼ Reference Countries
    ◼ Other Countries

Note

Acquired haemophilia :
● Cost/Unit: 5395,61 EUR ( 522,646,020.00 LBP )
● Cost/Day: 10791,22 EUR ( 1,045,388,916.00 LBP )
● Cost/Month: 10791,22 EUR ( 1,045,388,916.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 5395,61 EUR ( 522,646,020.00 LBP )
● Cost/Day: 10791,22 EUR ( 1,045,388,916.00 LBP )
● Cost/Month: 10791,22 EUR ( 1,045,388,916.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 5395,61 EUR ( 522,646,020.00 LBP )
● Cost/Day: 10791,22 EUR ( 1,045,388,916.00 LBP )
● Cost/Month: 10791,22 EUR ( 1,045,388,916.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 5395,61 EUR ( 522,646,020.00 LBP )
● Cost/Day: 10791,22 EUR ( 1,045,388,916.00 LBP )
● Cost/Month: 10791,22 EUR ( 1,045,388,916.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 5395,61 EUR ( 522,646,020.00 LBP )
● Cost/Day: 10791,22 EUR ( 1,045,388,916.00 LBP )
● Cost/Month: 10791,22 EUR ( 1,045,388,916.00 LBP )
Acquired haemophilia :
● Cost/Unit: 19816 QAR ( 486,641,328.00 LBP )
● Cost/Day: 39632 QAR ( 973,282,656.00 LBP )
● Cost/Month: 39632 QAR ( 973,282,656.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 19816 QAR ( 486,641,328.00 LBP )
● Cost/Day: 39632 QAR ( 973,282,656.00 LBP )
● Cost/Month: 39632 QAR ( 973,282,656.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 19816 QAR ( 486,641,328.00 LBP )
● Cost/Day: 39632 QAR ( 973,282,656.00 LBP )
● Cost/Month: 39632 QAR ( 973,282,656.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 19816 QAR ( 486,641,328.00 LBP )
● Cost/Day: 39632 QAR ( 973,282,656.00 LBP )
● Cost/Month: 39632 QAR ( 973,282,656.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 19816 QAR ( 486,641,328.00 LBP )
● Cost/Day: 39632 QAR ( 973,282,656.00 LBP )
● Cost/Month: 39632 QAR ( 973,282,656.00 LBP )
Acquired haemophilia :
● Cost/Unit: 2086,42 OMR ( 481,311,124.00 LBP )
● Cost/Day: 4172,84 OMR ( 962,622,248.00 LBP )
● Cost/Month: 4172,84 OMR ( 962,622,248.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 2086,42 OMR ( 481,311,124.00 LBP )
● Cost/Day: 4172,84 OMR ( 962,622,248.00 LBP )
● Cost/Month: 4172,84 OMR ( 962,622,248.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 2086,42 OMR ( 481,311,124.00 LBP )
● Cost/Day: 4172,84 OMR ( 962,622,248.00 LBP )
● Cost/Month: 4172,84 OMR ( 962,622,248.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 2086,42 OMR ( 481,311,124.00 LBP )
● Cost/Day: 4172,84 OMR ( 962,622,248.00 LBP )
● Cost/Month: 4172,84 OMR ( 962,622,248.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 2086,42 OMR ( 481,311,124.00 LBP )
● Cost/Day: 4172,84 OMR ( 962,622,248.00 LBP )
● Cost/Month: 4172,84 OMR ( 962,622,248.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1596,98 KWD ( 468,555,276.00 LBP )
● Cost/Day: 3193,96 KWD ( 937,404,133.00 LBP )
● Cost/Month: 3193,96 KWD ( 937,404,133.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1596,98 KWD ( 468,555,276.00 LBP )
● Cost/Day: 3193,96 KWD ( 937,404,133.00 LBP )
● Cost/Month: 3193,96 KWD ( 937,404,133.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1596,98 KWD ( 468,555,276.00 LBP )
● Cost/Day: 3193,96 KWD ( 937,404,133.00 LBP )
● Cost/Month: 3193,96 KWD ( 937,404,133.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1596,98 KWD ( 468,555,276.00 LBP )
● Cost/Day: 3193,96 KWD ( 937,404,133.00 LBP )
● Cost/Month: 3193,96 KWD ( 937,404,133.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1596,98 KWD ( 468,555,276.00 LBP )
● Cost/Day: 3193,96 KWD ( 937,404,133.00 LBP )
● Cost/Month: 3193,96 KWD ( 937,404,133.00 LBP )
Acquired haemophilia :
● Cost/Unit: 4370,8 CHF ( 451,945,400.00 LBP )
● Cost/Day: 8741,6 CHF ( 903,994,220.00 LBP )
● Cost/Month: 8741,6 CHF ( 903,994,220.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 4370,8 CHF ( 451,945,400.00 LBP )
● Cost/Day: 8741,6 CHF ( 903,994,220.00 LBP )
● Cost/Month: 8741,6 CHF ( 903,994,220.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 4370,8 CHF ( 451,945,400.00 LBP )
● Cost/Day: 8741,6 CHF ( 903,994,220.00 LBP )
● Cost/Month: 8741,6 CHF ( 903,994,220.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 4370,8 CHF ( 451,945,400.00 LBP )
● Cost/Day: 8741,6 CHF ( 903,994,220.00 LBP )
● Cost/Month: 8741,6 CHF ( 903,994,220.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 4370,8 CHF ( 451,945,400.00 LBP )
● Cost/Day: 8741,6 CHF ( 903,994,220.00 LBP )
● Cost/Month: 8741,6 CHF ( 903,994,220.00 LBP )
Acquired haemophilia :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Acquired haemophilia :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 18517 AED ( 447,389,237.00 LBP )
● Cost/Day: 37034 AED ( 894,778,474.00 LBP )
● Cost/Month: 37034 AED ( 894,778,474.00 LBP )
Acquired haemophilia :
● Cost/Unit: 1761,26 BHD ( 418,649,574.00 LBP )
● Cost/Day: 3522,52 BHD ( 837,299,148.00 LBP )
● Cost/Month: 3522,52 BHD ( 837,299,148.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 1761,26 BHD ( 418,649,574.00 LBP )
● Cost/Day: 3522,52 BHD ( 837,299,148.00 LBP )
● Cost/Month: 3522,52 BHD ( 837,299,148.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 1761,26 BHD ( 418,649,574.00 LBP )
● Cost/Day: 3522,52 BHD ( 837,299,148.00 LBP )
● Cost/Month: 3522,52 BHD ( 837,299,148.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 1761,26 BHD ( 418,649,574.00 LBP )
● Cost/Day: 3522,52 BHD ( 837,299,148.00 LBP )
● Cost/Month: 3522,52 BHD ( 837,299,148.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1761,26 BHD ( 418,649,574.00 LBP )
● Cost/Day: 3522,52 BHD ( 837,299,148.00 LBP )
● Cost/Month: 3522,52 BHD ( 837,299,148.00 LBP )
Acquired haemophilia :
● Cost/Unit: 3888,15 EUR ( 376,653,888.00 LBP )
● Cost/Day: 7776,3 EUR ( 753,307,776.00 LBP )
● Cost/Month: 7776,3 EUR ( 753,307,776.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 3888,15 EUR ( 376,653,888.00 LBP )
● Cost/Day: 7776,3 EUR ( 753,307,776.00 LBP )
● Cost/Month: 7776,3 EUR ( 753,307,776.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 3888,15 EUR ( 376,653,888.00 LBP )
● Cost/Day: 7776,3 EUR ( 753,307,776.00 LBP )
● Cost/Month: 7776,3 EUR ( 753,307,776.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 3888,15 EUR ( 376,653,888.00 LBP )
● Cost/Day: 7776,3 EUR ( 753,307,776.00 LBP )
● Cost/Month: 7776,3 EUR ( 753,307,776.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 3888,15 EUR ( 376,653,888.00 LBP )
● Cost/Day: 7776,3 EUR ( 753,307,776.00 LBP )
● Cost/Month: 7776,3 EUR ( 753,307,776.00 LBP )
Acquired haemophilia :
● Cost/Unit: 26563,3 DKK ( 344,681,488.00 LBP )
● Cost/Day: 53126,6 DKK ( 689,362,976.00 LBP )
● Cost/Month: 53126,6 DKK ( 689,362,976.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 26563,3 DKK ( 344,681,488.00 LBP )
● Cost/Day: 53126,6 DKK ( 689,362,976.00 LBP )
● Cost/Month: 53126,6 DKK ( 689,362,976.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 26563,3 DKK ( 344,681,488.00 LBP )
● Cost/Day: 53126,6 DKK ( 689,362,976.00 LBP )
● Cost/Month: 53126,6 DKK ( 689,362,976.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 26563,3 DKK ( 344,681,488.00 LBP )
● Cost/Day: 53126,6 DKK ( 689,362,976.00 LBP )
● Cost/Month: 53126,6 DKK ( 689,362,976.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 26563,3 DKK ( 344,681,488.00 LBP )
● Cost/Day: 53126,6 DKK ( 689,362,976.00 LBP )
● Cost/Month: 53126,6 DKK ( 689,362,976.00 LBP )
Acquired haemophilia :
● Cost/Unit: 532896 ISK ( 343,717,920.00 LBP )
● Cost/Day: 1065792 ISK ( 687,435,840.00 LBP )
● Cost/Month: 1065792 ISK ( 687,435,840.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 532896 ISK ( 343,717,920.00 LBP )
● Cost/Day: 1065792 ISK ( 687,435,840.00 LBP )
● Cost/Month: 1065792 ISK ( 687,435,840.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 532896 ISK ( 343,717,920.00 LBP )
● Cost/Day: 1065792 ISK ( 687,435,840.00 LBP )
● Cost/Month: 1065792 ISK ( 687,435,840.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 532896 ISK ( 343,717,920.00 LBP )
● Cost/Day: 1065792 ISK ( 687,435,840.00 LBP )
● Cost/Month: 1065792 ISK ( 687,435,840.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 532896 ISK ( 343,717,920.00 LBP )
● Cost/Day: 1065792 ISK ( 687,435,840.00 LBP )
● Cost/Month: 1065792 ISK ( 687,435,840.00 LBP )
Acquired haemophilia :
● Cost/Unit: 85264,46 CZK ( 325,623,216.00 LBP )
● Cost/Day: 170528,92 CZK ( 651,246,432.00 LBP )
● Cost/Month: 170528,92 CZK ( 651,246,432.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 85264,46 CZK ( 325,623,216.00 LBP )
● Cost/Day: 170528,92 CZK ( 651,246,432.00 LBP )
● Cost/Month: 170528,92 CZK ( 651,246,432.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 85264,46 CZK ( 325,623,216.00 LBP )
● Cost/Day: 170528,92 CZK ( 651,246,432.00 LBP )
● Cost/Month: 170528,92 CZK ( 651,246,432.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 85264,46 CZK ( 325,623,216.00 LBP )
● Cost/Day: 170528,92 CZK ( 651,246,432.00 LBP )
● Cost/Month: 170528,92 CZK ( 651,246,432.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 85264,46 CZK ( 325,623,216.00 LBP )
● Cost/Day: 170528,92 CZK ( 651,246,432.00 LBP )
● Cost/Month: 170528,92 CZK ( 651,246,432.00 LBP )
Acquired haemophilia :
● Cost/Unit: 13202,15 SAR ( 312,095,280.00 LBP )
● Cost/Day: 26404,3 SAR ( 624,190,560.00 LBP )
● Cost/Month: 26404,3 SAR ( 624,190,560.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 13202,15 SAR ( 312,095,280.00 LBP )
● Cost/Day: 26404,3 SAR ( 624,190,560.00 LBP )
● Cost/Month: 26404,3 SAR ( 624,190,560.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 13202,15 SAR ( 312,095,280.00 LBP )
● Cost/Day: 26404,3 SAR ( 624,190,560.00 LBP )
● Cost/Month: 26404,3 SAR ( 624,190,560.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 13202,15 SAR ( 312,095,280.00 LBP )
● Cost/Day: 26404,3 SAR ( 624,190,560.00 LBP )
● Cost/Month: 26404,3 SAR ( 624,190,560.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 13202,15 SAR ( 312,095,280.00 LBP )
● Cost/Day: 26404,3 SAR ( 624,190,560.00 LBP )
● Cost/Month: 26404,3 SAR ( 624,190,560.00 LBP )
Acquired haemophilia :
● Cost/Unit: 2626 GBP ( 298,442,274.00 LBP )
● Cost/Day: 5252 GBP ( 596,884,548.00 LBP )
● Cost/Month: 5252 GBP ( 596,884,548.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 2626 GBP ( 298,442,274.00 LBP )
● Cost/Day: 5252 GBP ( 596,884,548.00 LBP )
● Cost/Month: 5252 GBP ( 596,884,548.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 2626 GBP ( 298,442,274.00 LBP )
● Cost/Day: 5252 GBP ( 596,884,548.00 LBP )
● Cost/Month: 5252 GBP ( 596,884,548.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 2626 GBP ( 298,442,274.00 LBP )
● Cost/Day: 5252 GBP ( 596,884,548.00 LBP )
● Cost/Month: 5252 GBP ( 596,884,548.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 2626 GBP ( 298,442,274.00 LBP )
● Cost/Day: 5252 GBP ( 596,884,548.00 LBP )
● Cost/Month: 5252 GBP ( 596,884,548.00 LBP )
Acquired haemophilia :
● Cost/Unit: 3062,98 EUR ( 296,634,312.00 LBP )
● Cost/Day: 6125,96 EUR ( 593,365,500.00 LBP )
● Cost/Month: 6125,96 EUR ( 593,365,500.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 3062,98 EUR ( 296,634,312.00 LBP )
● Cost/Day: 6125,96 EUR ( 593,365,500.00 LBP )
● Cost/Month: 6125,96 EUR ( 593,365,500.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 3062,98 EUR ( 296,634,312.00 LBP )
● Cost/Day: 6125,96 EUR ( 593,365,500.00 LBP )
● Cost/Month: 6125,96 EUR ( 593,365,500.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 3062,98 EUR ( 296,634,312.00 LBP )
● Cost/Day: 6125,96 EUR ( 593,365,500.00 LBP )
● Cost/Month: 6125,96 EUR ( 593,365,500.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 3062,98 EUR ( 296,634,312.00 LBP )
● Cost/Day: 6125,96 EUR ( 593,365,500.00 LBP )
● Cost/Month: 6125,96 EUR ( 593,365,500.00 LBP )
Acquired haemophilia :
● Cost/Unit: 3040 EUR ( 294,503,040.00 LBP )
● Cost/Day: 6080 EUR ( 589,006,080.00 LBP )
● Cost/Month: 6080 EUR ( 589,006,080.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 3040 EUR ( 294,503,040.00 LBP )
● Cost/Day: 6080 EUR ( 589,006,080.00 LBP )
● Cost/Month: 6080 EUR ( 589,006,080.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 3040 EUR ( 294,503,040.00 LBP )
● Cost/Day: 6080 EUR ( 589,006,080.00 LBP )
● Cost/Month: 6080 EUR ( 589,006,080.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 3040 EUR ( 294,503,040.00 LBP )
● Cost/Day: 6080 EUR ( 589,006,080.00 LBP )
● Cost/Month: 6080 EUR ( 589,006,080.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 3040 EUR ( 294,503,040.00 LBP )
● Cost/Day: 6080 EUR ( 589,006,080.00 LBP )
● Cost/Month: 6080 EUR ( 589,006,080.00 LBP )
Acquired haemophilia :
● Cost/Unit: 2662 EUR ( 257,883,912.00 LBP )
● Cost/Day: 5324 EUR ( 515,767,824.00 LBP )
● Cost/Month: 5324 EUR ( 515,767,824.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 2662 EUR ( 257,883,912.00 LBP )
● Cost/Day: 5324 EUR ( 515,767,824.00 LBP )
● Cost/Month: 5324 EUR ( 515,767,824.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 2662 EUR ( 257,883,912.00 LBP )
● Cost/Day: 5324 EUR ( 515,767,824.00 LBP )
● Cost/Month: 5324 EUR ( 515,767,824.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 2662 EUR ( 257,883,912.00 LBP )
● Cost/Day: 5324 EUR ( 515,767,824.00 LBP )
● Cost/Month: 5324 EUR ( 515,767,824.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 2662 EUR ( 257,883,912.00 LBP )
● Cost/Day: 5324 EUR ( 515,767,824.00 LBP )
● Cost/Month: 5324 EUR ( 515,767,824.00 LBP )
Acquired haemophilia :
● Cost/Unit: 30097 NOK ( 243,906,088.00 LBP )
● Cost/Day: 60194 NOK ( 487,812,176.00 LBP )
● Cost/Month: 60194 NOK ( 487,812,176.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 30097 NOK ( 243,906,088.00 LBP )
● Cost/Day: 60194 NOK ( 487,812,176.00 LBP )
● Cost/Month: 60194 NOK ( 487,812,176.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 30097 NOK ( 243,906,088.00 LBP )
● Cost/Day: 60194 NOK ( 487,812,176.00 LBP )
● Cost/Month: 60194 NOK ( 487,812,176.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 30097 NOK ( 243,906,088.00 LBP )
● Cost/Day: 60194 NOK ( 487,812,176.00 LBP )
● Cost/Month: 60194 NOK ( 487,812,176.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 30097 NOK ( 243,906,088.00 LBP )
● Cost/Day: 60194 NOK ( 487,812,176.00 LBP )
● Cost/Month: 60194 NOK ( 487,812,176.00 LBP )
Acquired haemophilia :
● Cost/Unit: 28482,76 SEK ( 239,476,656.00 LBP )
● Cost/Day: 56965,52 SEK ( 478,961,720.00 LBP )
● Cost/Month: 56965,52 SEK ( 478,961,720.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 28482,76 SEK ( 239,476,656.00 LBP )
● Cost/Day: 56965,52 SEK ( 478,961,720.00 LBP )
● Cost/Month: 56965,52 SEK ( 478,961,720.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 28482,76 SEK ( 239,476,656.00 LBP )
● Cost/Day: 56965,52 SEK ( 478,961,720.00 LBP )
● Cost/Month: 56965,52 SEK ( 478,961,720.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 28482,76 SEK ( 239,476,656.00 LBP )
● Cost/Day: 56965,52 SEK ( 478,961,720.00 LBP )
● Cost/Month: 56965,52 SEK ( 478,961,720.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 28482,76 SEK ( 239,476,656.00 LBP )
● Cost/Day: 56965,52 SEK ( 478,961,720.00 LBP )
● Cost/Month: 56965,52 SEK ( 478,961,720.00 LBP )
Acquired haemophilia :
● Cost/Unit: 12895,82 TRY ( 34,558,600.00 LBP )
● Cost/Day: 25791,64 TRY ( 69,119,880.00 LBP )
● Cost/Month: 25791,64 TRY ( 69,119,880.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 12895,82 TRY ( 34,558,600.00 LBP )
● Cost/Day: 25791,64 TRY ( 69,119,880.00 LBP )
● Cost/Month: 25791,64 TRY ( 69,119,880.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 12895,82 TRY ( 34,558,600.00 LBP )
● Cost/Day: 25791,64 TRY ( 69,119,880.00 LBP )
● Cost/Month: 25791,64 TRY ( 69,119,880.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 12895,82 TRY ( 34,558,600.00 LBP )
● Cost/Day: 25791,64 TRY ( 69,119,880.00 LBP )
● Cost/Month: 25791,64 TRY ( 69,119,880.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 12895,82 TRY ( 34,558,600.00 LBP )
● Cost/Day: 25791,64 TRY ( 69,119,880.00 LBP )
● Cost/Month: 25791,64 TRY ( 69,119,880.00 LBP )
Acquired haemophilia :
● Cost/Unit: 4222855 LBP ( 4,222,855.00 LBP )
● Cost/Day: 8445710 LBP ( 8,445,710.00 LBP )
● Cost/Month: 8445710 LBP ( 8,445,710.00 LBP )
Congenital FVII deficiency :
● Cost/Unit: 4222855 LBP ( 4,222,855.00 LBP )
● Cost/Day: 8445710 LBP ( 8,445,710.00 LBP )
● Cost/Month: 8445710 LBP ( 8,445,710.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX :
● Cost/Unit: 4222855 LBP ( 4,222,855.00 LBP )
● Cost/Day: 8445710 LBP ( 8,445,710.00 LBP )
● Cost/Month: 8445710 LBP ( 8,445,710.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII :
● Cost/Unit: 4222855 LBP ( 4,222,855.00 LBP )
● Cost/Day: 8445710 LBP ( 8,445,710.00 LBP )
● Cost/Month: 8445710 LBP ( 8,445,710.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 4222855 LBP ( 4,222,855.00 LBP )
● Cost/Day: 8445710 LBP ( 8,445,710.00 LBP )
● Cost/Month: 8445710 LBP ( 8,445,710.00 LBP )
Prices are provided in Dollar ($)
You have to register to view this info

You have to register to view this info

You have to register to view this info